Serum 1,5-anhydroglucitol (1,5-AG) is a useful clinical indicator for short-term glycemic control status, which exhibits a rapid decrease if blood glucose levels are poorly controlled in diabetic patients. Interestingly, some cross-sectional studies have suggested that serum 1,5-AG level decreases even before the onset of type 2 diabetes. Thus, the aim of the present study was to examine whether there is an association between a decrease in serum 1,5-AG level and the incidence of abnormal glucose metabolism (AbGM) or metabolic syndrome (MetS) in Japanese in a prospective cohort study. We here report a prospective occupational-based cohort study, which was conducted during 2010-2017 in Japan. Briefly, 1) 837 male workers without AbGM and 2) 843 male workers without MetS aged over 20 years were followed up prospectively. AbGM was defined as either: 1) fasting plasma glucose ≥ 110 mg/dl, 2) HbA1c ≥ 6.0% or 3) medication for hyperglycemia. In multivariate analysis after adjusting for age, BMI, smoking habit, alcohol intake, regular exercise and estimated glomerular filtration rate, the HR of developing MetS was 1.81 [95%CI: 1.12 to 2.92, P=0.01] in the lowest quartile of baseline serum 1,5-AG, compared with the highest quartile. In addition, the incidence and multivariate-adjusted HR of AbGM or MetS also increased with decreasing quartile of serum 1,5-AG (P for trend for both <0.05). Our findings suggest that a decrease in serum 1,5-AG level is a predictive marker for the future onset of AbGM or MetS in male Japanese.
A. Hata: None. N. Aki: None. T. Ichihara: None. A. Tamura: None. T. Minagawa: None. Y. Kuwamura: None. M. Funaki: None.